Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Pharmacol Res. 2019 Sep;147:104389. doi: 10.1016/j.phrs.2019.104389. Epub 2019 Aug 12.
The use of biologic disease modifying antirheumatic drugs (bDMARDs) in systemic autoimmune diseases such as rheumatoid arthritis and at a lesser extent in lupus, has been well established. In Sjögren's syndrome (SS), despite the shared pathogenetic mechanisms with other autoimmune disorders, traditional immunomodulatory drugs have failed to address the main clinical features of the disease and use of biologics has been limited so far. Over the last years, our better understanding in disease pathogenesis has led to an expansion in the number of clinical trials exploring the effect and safety of biological agents with variable results. In the current review, the effect of targeting key molecular mechanisms involved in SS pathogenesis such as antigen presentation, B and T cell activation and germinal center formation is discussed.
在类风湿关节炎和狼疮等系统性自身免疫性疾病中，生物疾病修饰抗风湿药物（bDMARDs）的应用已经得到充分证实。在干燥综合征（SS）中，尽管与其他自身免疫性疾病具有共同的发病机制，但传统的免疫调节剂未能解决该疾病的主要临床特征，因此生物制剂的应用至今受到限制。近年来，我们对疾病发病机制的认识不断深入，导致了越来越多的临床试验探索生物制剂的作用和安全性，结果各不相同。在本次综述中，讨论了针对 SS 发病机制中关键分子机制（如抗原呈递、B 和 T 细胞激活以及生发中心形成）的治疗效果。
